Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50-100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range, 0.04-0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value <0.5 g/g Cr (median podocyturia, 1.08 cells/mg Cr, range, 0-14.55 vs. 0.03 cells/mg Cr, range, 0-1.64, respectively; p < 0.001). A statistically significant correlation was observed between the cumulative dose of bevacizumab and both proteinuria (r = 0.48, p = 0.004) and podocyturia (r = 0.34, p = 0.045) as well as between proteinuria and podocyturia (r = 0.63, p < 0.001), suggesting that these are mechanistically related. Discussion: Ongoing podocyte loss may be mechanistically related to the onset and severity of proteinuria in patients treated with anti-VEGF agents.

Keywords:
Podocyturia, Proteinuria, Antivascular endothelial growth factor therapy, Malignancy, Hypertension
1.
Granger JP: Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension 2009;54:465-467.
2.
Maharaj A, D'Amore PA: Roles for VEGF in the adult. Microvasc Res 2007;74:100-113.
3.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
4.
Daniels BS: The role of the glomerular epithelial cell in the maintenance of the glomerular filtration barrier. Am J Nephrol 1993;13:318-323.
5.
Barisoni L, Mundel P: Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol 2003;23:353-360.
6.
Kennedy C: What type of VEGF do you need? J Am Soc Nephrol 2010;21:1410-1412.
7.
Qiu Y, Ferguson J, Oltean S, et al: Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 2010;21:1498-1509.
8.
Parikh SM, Pollak MR: VEGF receptors and glomerular function. J Am Soc Nephrol 2010;21:1599-1600.
9.
Genentech: Avastin (bevacizumab) [Product insert], South San Francisco, Genentech, 2009.
10.
Gurevich F, Perazella MA: Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122:322-328.
11.
Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-1795.
12.
Launay-Vacher V, Deray G: Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009;20:81-82.
13.
Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-193.
14.
Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21:1381-1389.
15.
Halimi JM, Azizi M, Bobrie G, et al: Vascular and renal effects of anti-angiogenic therapy (in French). Nephrol Ther 2008;4:602-615.
16.
Yu D, Petermann A, Kunter U, Rong S, Shankland S, Floege J: Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005;16:1733-1741.
17.
Vogelmann SU, Nelson WJ, Myers BD, Lemley KV: Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003;285:F40-F48.
18.
Nakamura T, Ushiyama C, Suzuki S, et al: Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000;320:112-116.
19.
Nakamura T, Ushiyama C, Suzuki S, et al: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000;15:1379-1383.
20.
Hara M, Yanagihara T, Takada T, et al: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998;18:35-41.
21.
Nakamura T, Ushiyama C, Suzuki S, et al: The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000;20:175-179.
22.
Garovic VD, Wagner SJ, Turner ST, et al: Urinary podocyte excretion as a marker of preeclampsia. Am J Obstet Gynecol 2007;196:320.e1-e7.
23.
Maynard SE, Min JY, Merchan J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
24.
Müller-Deile J, Bröcker V, Grünwald V, et al: Renal side effects of VEGF-blocking therapy. NDT Plus 2010;3:172-175.
25.
Wilson DM, Anderson RL: Protein-osmolality ratio for the quantitative assessment of proteinuria from a random urinalysis sample. Am J Clin Pathol 1993;100:419-424.
26.
Morgenstern BZ, Butani L, Wollan P, Wilson DM, Larson TS: Validity of protein-osmolality versus protein-creatinine ratios in the estimation of quantitative proteinuria from random samples of urine in children. Am J Kidney Dis 2003;41:760-766.
27.
Levey AS, Coresh J, Greene T, et al: Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-772.
28.
Petermann AT, Krofft R, Blonski M, et al: Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 2003;64:1222-1231.
29.
Appel D, Kershaw DB, Smeets B, et al: Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009;20:333-343.
30.
Lasgni L, Romagnani P: Glomerular epithelial stem cells: the good, the bad, and the ugly. J Am Soc Nephrol 2010;21:1612-1619.
31.
Sato Y, Wharram BL, Lee SK, et al: Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 2009;20:1041-1052.
32.
Szeto CC, Lai KB, Chow KM, et al: Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin Chim Acta 2005;361:182-190.
33.
Haraldsson B, Jeansson M: Glomerular filtration barrier. Curr Opin Nephrol Hypertens 2009;18:331-335.
34.
Menzel S, Moeller MJ: Role of the podocyte in proteinuria. Pediatr Nephrol 2011;26:1775-1780.
35.
Skoberne A, Konieczny A, Schiffer M: Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Phisiol Renal Physiol 2009;296:F230-F241.
36.
Garovic VD, Wagner SJ, Petrovic LM, et al: Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007;22:1136-1143.
37.
Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136.
38.
Sugimoto H, Hamano Y, Charytan D, et al: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-12608.
39.
Sison K, Eremina V, Baelde H, et al: Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010;21:1691-1701.
40.
Hayman SR, Leung N, Grande JP, Garovic VD: VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012;14:285-294.
41.
Lanctot L, Naranjo CA: Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther 1995;58:692-698.
42.
Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients. A meta-analysis. JAMA 2011;305:487-494.
43.
Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P: Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011;104:599-604.
44.
Garovic VD, Craici IM, Wagner SJ, et al: Mass spectrometry as a novel method for detection of podocyturia in preeclampsia. Nephrol Dial Transplant 2013;28:1555-1561.
45.
Craici IM, Wagner SJ, Bailey KR, et al: Podocyturia predates proteinuria and clinical features of preeclampsia - longitudinal prospective study. Hypertension 2013;61:1289-1296.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.